Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the following virtual investor conferences in June.
May 27, 2021
· 1 min read